Nkarta Announces Pricing of Upsized Public Offering of Common Stock
25 Abril 2022 - 10:19PM
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing
engineered natural killer cell therapies to treat cancer, today
announced the pricing of an underwritten public offering of
13,333,334 shares of its common stock at a price to the public of
$15.00 per share. The Company has granted the underwriters a 30-day
option to purchase up to 2,000,000 additional shares of its common
stock at the public offering price, less underwriting discounts and
commissions. All shares in the offering are to be issued and sold
by Nkarta.
The offering is expected to close on or about April 28, 2022,
subject to customary closing conditions.
Gross proceeds to Nkarta from this offering are approximately
$200 million, before deducting underwriting discounts and
commissions and offering expenses and assuming no exercise of the
underwriters’ option to purchase additional shares. Nkarta intends
to use the net proceeds from the offering to fund the continued
clinical development of NKX101 and NKX019, preclinical studies for
research stage programs and the continued buildout of internal
manufacturing capabilities, and for working capital and for general
corporate purposes.
Cowen, SVB Securities, Evercore ISI and Stifel are acting as
joint book-running managers for the offering.
The offering was conducted pursuant to a shelf registration
statement (File No. 333-258766), which was filed with the
Securities and Exchange Commission (“SEC”) on August 12, 2021 and
declared effective by the SEC on September 2, 2021. The offering
was made only by means of a prospectus supplement and accompanying
prospectus describing the terms of the offering. Copies of the
final prospectus supplement and the accompanying prospectus
relating to this offering may be obtained by contacting the
following: Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention:
Prospectus Department, by telephone at (833) 297-2926, or by email
at PostSaleManualRequests@broadridge.com; SVB Securities LLC,
Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by
email at syndicate@svbsecurities.com; Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor,
New York, NY 10055, by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com; and Stifel, Nicolaus & Company,
Incorporated, Attention: Prospectus Department, One Montgomery
Street, Suite 3700, San Francisco, CA 94104 or by telephone at
(415) 364-2720 or by email at syndprospectus@stifel.com. These
documents may also be obtained for free on the SEC’s website
located at http://www.sec.gov. The final terms of the offering will
be disclosed in a final prospectus supplement to be filed with the
SEC.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any offer, solicitation or sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or
jurisdiction.
Cautionary Note on Forward-Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Words such as
"anticipates," "believes," "expects," "intends," “plans,”
“potential,” "projects,” “would,” and "future" or similar
expressions are intended to identify forward-looking statements.
Examples of these forward-looking statements include statements
concerning the expected net proceeds from the offering and the
Nkarta’s use of such proceeds and the timing of completion of the
offering. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, among others, the risks identified
in Nkarta’s filings with the SEC, including those discussed in the
section captioned “Risk Factors” contained in Nkarta’s Annual
Report on Form 10-K filed with the SEC on March 17, 2022, the
preliminary prospectus supplement related to the proposed public
offering and Nkarta’s other documents subsequently filed with or
furnished to the SEC. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Except to the extent required by law, Nkarta undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
About NkartaNkarta is a clinical-stage
biotechnology company advancing the development of allogeneic,
off-the-shelf natural killer (NK) cell therapies for cancer
patients. By combining its cell expansion and cryopreservation
platform with proprietary cell engineering technologies and
CRISPR-based genome engineering capabilities, Nkarta is building a
pipeline of future cell therapies engineered for deep anti-tumor
activity and intended for broad access in the outpatient treatment
setting.
Nkarta Media/Investor Contact:Greg MannNkarta,
Inc.gmann@nkartatx.com
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024